The VEGFR inhibitors market is evolving rapidly due to rising prevalence of oncology and ophthalmology indications, new drug approvals, and expanding biologics and small‑molecule therapies. Discover detailed segmentation by indication and region, investment trends, reimbursement landscape, and projected growth through 2026 and beyond. https://www.datamintelligence.com/research-report/vascular-endothelial-growth-factor-receptor-inhibitors-market